#USA #San Diego #Class Action #Securities Fraud #ADMA Biologics

Opportunity for ADMA Biologics, Inc. Investors

ADMA Biologics, Inc. is currently facing a class action lawsuit spearheaded by Robbins Geller Rudman & Dowd LLP that provides an opportunity for investors who have experienced substantial losses. If you purchased publicly traded ADMA Biologics securities between August 9, 2024, and March 25, 2026, you may have a chance to become the lead plaintiff in this case, which focuses on potential violations of the Securities Exchange Act of 1934.

Background of the Case

The lawsuit labeled Mazzarino v. ADMA Biologics, Inc. (No. 26-cv-06918) accuses the company and several top executives of misleading investors. The complaint asserts that ADMA Biologics engaged in practices that compromised transparency and violated securities laws. Reports surfaced during the class period alleging that ADMA Biologics partook in undisclosed related party transactions, inflated its revenue figures through questionable practices known as channel stuffing, and failed to establish adequate internal controls.

On March 24, 2026, Culper Research released a critical report on ADMA Biologics, alleging that their reported growth was largely fictitious, driven by deceptive practices rather than genuine market performance. This report indicated that the company would have experienced a decline in revenue if proper accounting standards had been applied. Following the release, ADMA's stock price witnessed a sharp decline of over 16%.

ADMA's subsequent response attempted to refute these allegations, claiming that the report was based on unreliable information. However, investor sentiment remained shaky, leading to another stock price decline of more than 13% after analysts downgrading ADMA's stock rating.

Details of the Lead Plaintiff Process

The Private Securities Litigation Reform Act of 1995 allows any investor affected during the class period to apply as the lead plaintiff. The lead plaintiff typically holds the most significant financial interest in the class’s claims and represents all other class members in directing the case. It's important to note that an investor’s ability to recover potential damages does not rely on their role as the lead plaintiff.

Why Join the Class Action?

This class action offers an avenue for investors to seek restitution for financial losses incurred due to alleged manipulative practices. Being part of the class action gives investors a collective voice against ADMA Biologics and its executives, ensuring that accountability can be pursued.

If you qualify based on your investment in ADMA Biologics securities during the defined period and wish to seek the lead plaintiff role, you are encouraged to provide your information to Robbins Geller or contact their attorneys directly for more guidance.

About Robbins Geller

Robbins Geller Rudman & Dowd LLP is a notable law firm recognized for its representation of investors in securities fraud cases. In recent years, the firm has secured over $916 million for investors, consistently ranked number one for its recoveries in the industry. With a robust team of attorneys, Robbins Geller has established itself as a leader in protecting shareholder rights and resolving complex securities litigation.

For more information about joining the class action or learning about your rights as an investor, please visit Robbins Geller’s dedicated page, or reach out to the firm through the provided contact information.

Conclusion

The ADMA Biologics class action lawsuit signifies a significant opportunity for injured investors to recover losses and seek justice. With the deadline looming on August 10, 2026, affected investors must act quickly to ensure their participation. This lawsuit stands as a testament to the vigilance required in the investing landscape and the importance of corporate accountability.